Piper Sandler analyst David Amsellem raised the firm’s price target on Revance Therapeutics to $40 from $29 and keeps an Overweight rating on the shares after conducting a survey of 26 dermatologists and cosmetic surgeons who are frequent users of aesthetic facial injectables, particularly dermal fillers. The feedback surrounding Revance’s dermal filler franchise was encouraging and suggestive of a continued growing footprint for the product line, the analyst tells investors in a research note. Piper continues to believe Daxxify is well positioned for significant commercial success.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVNC: